The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
If approved, DTX401 would be the first treatment to address the disease at its root cause
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
Subscribe To Our Newsletter & Stay Updated
